B-cell maturation antigen (BCMA), also known as CD269, is a member of the tumor necrosis factor superfamily, which is mainly expressed on plasma cells, and plasmacytoid dendritic cells, but not other normal cells, considered to be an ideal target for CAR-T cells in the treatment of R/R MM [8–10]. Here, TNFRSF17 is linked to Miyoshi myopathy.